Aliases & Classifications for Ureter, Cancer of

MalaCards integrated aliases for Ureter, Cancer of:

Name: Ureter, Cancer of 58
Ureter Carcinoma 12 56 15 17 74
Ureteral Neoplasms 45 74
Ureter Cancer 12 15
Malignant Neoplasm of Ureter 74
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Ureteral Carcinoma 12
Ureteral Neoplasm 17

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
ureter, cancer of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11819 DOID:4939
OMIM 58 191600
ICD9CM 36 189.2
MeSH 45 D014516
NCIt 51 C7543 C8993
SNOMED-CT 69 94121005
ICD10 34 C66
MedGen 43 C0153619
SNOMED-CT via HPO 70 126882009 263681008 363458004

Summaries for Ureter, Cancer of

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter, Cancer of, also known as ureter carcinoma, is related to regional ureteric cancer and ureter adenocarcinoma. An important gene associated with Ureter, Cancer of is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Endochondral Ossification and Lung fibrosis. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, kidney and the ureter, and related phenotypes are neoplasm of the ureter and growth/size/body region

Description from OMIM: 191600

Related Diseases for Ureter, Cancer of

Diseases related to Ureter, Cancer of via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 regional ureteric cancer 11.3
2 ureter adenocarcinoma 11.1
3 perforated corneal ulcer 10.0 PLAU PLAUR
4 paranasal sinus disease 9.9 PLAU PLAUR
5 hydronephrosis 9.9
6 paroxysmal nocturnal hemoglobinuria 9.8 PLAU PLAUR
7 werner syndrome 9.8
8 salla disease 9.8
9 anuria 9.8
10 urinary tract obstruction 9.8
11 in situ carcinoma 9.8

Comorbidity relations with Ureter, Cancer of via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Cancer
Deficiency Anemia Hydronephrosis
Prostatic Hypertrophy Renal Pelvis Carcinoma

Graphical network of the top 20 diseases related to Ureter, Cancer of:



Diseases related to Ureter, Cancer of

Symptoms & Phenotypes for Ureter, Cancer of

Human phenotypes related to Ureter, Cancer of:

33
# Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 33 HP:0100516

Symptoms via clinical synopsis from OMIM:

58
G U:
cancer of ureter

Clinical features from OMIM:

191600

MGI Mouse Phenotypes related to Ureter, Cancer of:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.63 ANKRD11 MGP PLAU PLAUR PNLIP TERT
2 homeostasis/metabolism MP:0005376 9.43 ANKRD11 MGP PLAU PLAUR PNLIP TERT
3 respiratory system MP:0005388 8.92 MGP PLAU PLAUR TERT

Drugs & Therapeutics for Ureter, Cancer of

Drugs for Ureter, Cancer of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
2
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
3
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
5
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
6
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
7
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
9
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
10
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
12
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
13
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
14
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
15
Bevacizumab Approved, Investigational Phase 3 216974-75-3
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
18
Cobalamin Experimental Phase 3 13408-78-1 6857388
19
Doxil Approved June 1999 Phase 3,Phase 1,Phase 2 31703
20 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
21 Immunologic Factors Phase 3,Phase 1,Phase 2
22 Antimetabolites Phase 3,Phase 1,Phase 2
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
25 Antiviral Agents Phase 3,Phase 1,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
27 Immunoglobulins Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Albumin-Bound Paclitaxel Phase 3,Phase 2
30 Antibodies Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 3,Phase 1
34 Angiogenesis Modulating Agents Phase 3,Phase 1
35 Vitamin B12 Phase 3
36 Vitamins Phase 3,Phase 2
37 Vitamin B Complex Phase 3,Phase 2
38 Vitamin B9 Phase 3,Phase 2
39 HIV Protease Inhibitors Phase 3
40
protease inhibitors Phase 3
41 Trace Elements Phase 3,Phase 2
42 Hormones Phase 3,Phase 2,Phase 1
43 Gastrointestinal Agents Phase 3
44 Antiemetics Phase 3
45 Antineoplastic Agents, Hormonal Phase 3
46 Folate Phase 3,Phase 2
47 glucocorticoids Phase 3
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
49 Hematinics Phase 3
50 Folic Acid Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
2 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
3 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
4 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
5 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Active, not recruiting NCT01993979 Phase 3 Chemotherapy
6 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
7 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
8 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
9 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
10 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
11 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
12 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
13 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel
14 Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Recruiting NCT03520231 Phase 2 Denosumab;Gemcitabine;Carboplatin;Cisplatin
15 Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Recruiting NCT03179943 Phase 2 Atezolizumab;Guadecitabine
16 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Recruiting NCT03513952 Phase 2 Atezolizumab
17 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
18 Afatinib in Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
19 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
20 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
21 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Active, not recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
22 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
23 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Suspended NCT03397394 Phase 2 Rucaparib
24 A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy Terminated NCT01234519 Phase 1, Phase 2 AEZS-108;AEZS-108 at MTD
25 DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Terminated NCT01353222 Phase 2
26 Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Withdrawn NCT01639521 Phase 2 cisplatin;gemcitabine hydrochloride;methotrexate;vinblastine;doxorubicin hydrochloride
27 Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Completed NCT01182168 Phase 1 gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
28 Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Completed NCT01352962 Phase 1 Gemcitabine;Carboplatin;Lenalidomide
29 Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Completed NCT01844947 Phase 1 Vinflunine;Sorafenib
30 Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery Recruiting NCT02812420 Phase 1
31 A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting NCT03590054 Phase 1 Abexinostat
32 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib;Cabozantinib S-malate
33 Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Active, not recruiting NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
34 Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Active, not recruiting NCT00479128 Phase 1 Bortezomib;Gemcitabine;Doxorubicin
35 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Active, not recruiting NCT02443324 Phase 1 Ramucirumab;Pembrolizumab
36 CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma Completed NCT03013920
37 Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. Completed NCT00263107
38 Familial and Atypical Urothelial Cancer Registry Recruiting NCT00902590
39 Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Recruiting NCT03291028
40 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
41 UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch Active, not recruiting NCT02643043 Not Applicable
42 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers Active, not recruiting NCT01846520 Not Applicable

Search NIH Clinical Center for Ureter, Cancer of

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter, Cancer of

Anatomical Context for Ureter, Cancer of

MalaCards organs/tissues related to Ureter, Cancer of:

42
Endothelial, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter, Cancer of:

20
The Ureter

Publications for Ureter, Cancer of

Articles related to Ureter, Cancer of:

# Title Authors Year
1
Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer. ( 24202956 )
2014
2
Papillary urothelial carcinoma in sigmoid neobladder suggesting 'intraluminal seeding' from ureter cancer. ( 19138291 )
2008
3
Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. ( 17725112 )
2007
4
The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. ( 2606581 )
1989
5
The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. ( 3356489 )
1988

Variations for Ureter, Cancer of

Expression for Ureter, Cancer of

Search GEO for disease gene expression data for Ureter, Cancer of.

Pathways for Ureter, Cancer of

Pathways related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 MGP PLAU
2 11.17 PLAU TERT
3 11.11 PLAU PLAUR
4 10.94 PLAU PLAUR
5 10.83 PLAU PLAUR
6 10.33 MGP PLAU PLAUR
7 10.07 PLAU PLAUR

GO Terms for Ureter, Cancer of

Cellular components related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 specific granule membrane GO:0035579 8.62 PLAU PLAUR

Biological processes related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.62 PLAU PLAUR

Sources for Ureter, Cancer of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....